title: RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
abstract: OBJECTIVE
  To investigate reticular pseudodrusen (RPD) as a potential baseline factor predictive of a poor 1-year response to intravitreal ranibizumab in eyes with neovascular age-related macular degeneration.
  
  
  METHODS
  Retrospective, monocentric case series including 98 consecutive naive neovascular age-related macular degeneration patients. Presence of RPD was assessed by two graders based on color, blue-light, fundus autofluorescence pictures, and spectral-domain optical coherence tomography. A correlation between the presence of RPD and the visual change was investigated. Other baseline characteristics studied in a monovariate and multivariate analysis were the following: age, gender, affected side, loading dose, type of neovascularization, presence of retinal pigment epithelial detachment >250 μm, subretinal or intraretinal fluid, blood over >50% of the lesion, and subfoveal choroidal thickness.
  
  
  RESULTS
  The presence of RPD was not associated with a visual change (P = 0.96), but with a thin subfoveal choroidal thickness at baseline (P < 0.0001). The monovariate analysis showed that the presence of blood at baseline was associated with visual gain (P = 0.007).
  
  
  CONCLUSIONS
  The presence of RPD at baseline was not identified as a factor associated with a poor 1-year response to ranibizumab in eyes with neovascular age-related macular degeneration. Studies with a longer follow-up may be needed to assess the impact of RPD on the visual prognosis of eyes with neovascular age-related macular degeneration.
authors.affiliation: *Ophthalmic Center for Imaging and Laser, Paris, France; †Department of Ophthalmology, Avicenne Hospital, AP-HP and University Paris 13, Bobigny, France; ‡Center for Clinical and Biological Research, Intercity Hospital, Créteil, France; and §Department of Ophthalmology, Intercity Hospital and University Paris Est, Créteil, France.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.forename: Audrey
authors.initials: A
authors.lastname: Giocanti-Auregan
authors.forename: Camille
authors.initials: C
authors.lastname: Jung
authors.forename: Lise
authors.initials: L
authors.lastname: Dubois
authors.forename: Pauline
authors.initials: P
authors.lastname: Dourmad
authors.forename: Lea
authors.initials: L
authors.lastname: Galbadon
authors.forename: Franck
authors.initials: F
authors.lastname: Fajnkuchen
authors.forename: Gabriel
authors.initials: G
authors.lastname: Quentel
authors.forename: Salomon Y
authors.initials: SY
authors.lastname: Cohen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D002829:Choroid / Q000473:pathology; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D000069579:Ranibizumab / Q000008:administration & dosage* / Q000627:therapeutic use; D015593:Retinal Drusen / Q000473:pathology*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab